Lysosomal dysfunction in neurodegeneration: emerging concepts and methods
V Udayar, Y Chen, E Sidransky, R Jagasia - Trends in neurosciences, 2022 - cell.com
The understanding of lysosomes has come a long way since the initial discovery of their role
in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle …
in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle …
LRRK2 and idiopathic Parkinson's disease
The etiology of idiopathic Parkinson's disease (iPD) is multifactorial, and both genetics and
environmental exposures are risk factors. While mutations in leucine-rich repeat kinase-2 …
environmental exposures are risk factors. While mutations in leucine-rich repeat kinase-2 …
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease
D Jennings, S Huntwork-Rodriguez, AG Henry… - Science translational …, 2022 - science.org
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factors
for Parkinson's disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal …
for Parkinson's disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal …
LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease
D Jennings, S Huntwork‐Rodriguez… - Movement …, 2023 - Wiley Online Library
Background Leucine‐rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic
approach for the treatment of Parkinson's disease (PD). Objective The aim of this study was …
approach for the treatment of Parkinson's disease (PD). Objective The aim of this study was …
[HTML][HTML] The role of extracellular vesicles in the physiological and pathological regulation of the blood–brain barrier
Extracellular vesicles (EVs) are a subclass of biological nanoparticles secreted by most cell
types. Once secreted, EVs can travel long distances to deliver their content to target cells …
types. Once secreted, EVs can travel long distances to deliver their content to target cells …
Elevated urinary Rab10 phosphorylation in idiopathic Parkinson disease
Background Pathogenic leucine‐rich repeat kinase 2 LRRK2 mutations may increase
LRRK2 kinase activity and Rab substrate phosphorylation. Genetic association studies link …
LRRK2 kinase activity and Rab substrate phosphorylation. Genetic association studies link …
[HTML][HTML] Single molecule array measures of LRRK2 kinase activity in serum link Parkinson's disease severity to peripheral inflammation
Background LRRK2-targeting therapeutics that inhibit LRRK2 kinase activity have advanced
to clinical trials in idiopathic Parkinson's disease (iPD). LRRK2 phosphorylates Rab10 on …
to clinical trials in idiopathic Parkinson's disease (iPD). LRRK2 phosphorylates Rab10 on …
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism
Missense mutations in the LRRK2 gene were first identified as a pathogenic cause of
Parkinson's disease (PD) in 2004. Soon thereafter, a founder mutation in LRRK2, p. G2019S …
Parkinson's disease (PD) in 2004. Soon thereafter, a founder mutation in LRRK2, p. G2019S …
A potential patient stratification biomarker for Parkinson´ s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells
Y Naaldijk, B Fernández, R Fasiczka, E Fdez… - npj Parkinson's …, 2024 - nature.com
Parkinson´ s disease (PD) is a common neurodegenerative movement disorder and leucine-
rich repeat kinase 2 (LRRK2) is a promising therapeutic target for disease intervention …
rich repeat kinase 2 (LRRK2) is a promising therapeutic target for disease intervention …
Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease
Mutations in Leucine-rich repeat kinase 2 (LRRK2) are a risk factor for and a cause of
sporadic and familial Parkinson's disease (PD), respectively. These mutations are some of …
sporadic and familial Parkinson's disease (PD), respectively. These mutations are some of …